FDA Alerts
FDA Offers New Guidance on Developing Drugs for Alzheimer’s Disease
Today, the US Food and Drug Administration issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer’s disease, before the onset of noticeable (overt) dementia.
New Drug for Alzheimer's Disease
The U.S. Food and Drug Administration approved Amyvid ( Florbetapir F 18 Injection) a drug for Positron Emission Tomography (PET) imaging of the brain in adults who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.